{"id":3768,"date":"2026-11-17T18:43:38","date_gmt":"2026-11-17T18:43:38","guid":{"rendered":"https:\/\/tansan.com.tr\/?page_id=3768"},"modified":"2026-11-17T20:32:23","modified_gmt":"2026-11-17T20:32:23","slug":"erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler","status":"publish","type":"page","link":"https:\/\/tansan.com.tr\/en\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/","title":{"rendered":"New Developments in Early-Stage Breast Cancer Treatment"},"content":{"rendered":"<p>Erken evre meme kanserinde tedavinin amac\u0131, hastal\u0131\u011f\u0131 ortadan kald\u0131rmak ve yeniden ortaya \u00e7\u0131kma riskini azaltmakt\u0131r. Son y\u0131llardaki geli\u015fmeler, bu hedefe ula\u015f\u0131rken kimin daha yo\u011fun tedaviye ihtiya\u00e7 duydu\u011funu, kimde ise baz\u0131 tedavilerin azalt\u0131labilece\u011fini daha iyi anlamam\u0131z\u0131 sa\u011fl\u0131yor. Kararlar; t\u00fcm\u00f6r\u00fcn \u00f6zellikleri, lenf bezlerinin durumu ve hastan\u0131n ya\u015fam\u0131 birlikte de\u011ferlendirilerek, cerrahi, t\u0131bbi onkoloji, radyasyon onkolojisi ve patoloji uzmanlar\u0131n\u0131n ortak \u00e7al\u0131\u015fmas\u0131yla veriliyor.<\/p>\n<p>Tedavi plan\u0131n\u0131n temelinde \u00f6strojen ve progesteron resept\u00f6rleri ile HER2 sonucu yer al\u0131yor. Hormon resept\u00f6r\u00fc pozitif, HER2 negatif hastal\u0131kta, uygun hastalara yap\u0131lan t\u00fcm\u00f6r\u00fcn gen etkinli\u011fini \u00f6l\u00e7en testler kemoterapiden beklenen yarar\u0131 de\u011ferlendirmeye yard\u0131mc\u0131 olabiliyor. B\u00f6ylece baz\u0131 hastalarda hormon tedavisiyle yetinmek m\u00fcmk\u00fcn oluyor. Ancak ya\u015f, menopoz durumu ve lenf bezi tutulumu da \u00f6nem ta\u015f\u0131yor; tek bir test sonucu herkes i\u00e7in ayn\u0131 karar\u0131 vermiyor. [1]\n<p>Hormon resept\u00f6r\u00fc pozitif, HER2 negatif ve tekrarlama riski y\u00fcksek hastal\u0131kta hormon tedavisine abemasiklib veya ribosiklib gibi CDK4\/6 inhibit\u00f6rlerinin eklenmesi, uygun hastalarda ek koruma sa\u011flayabiliyor. Bu iki ila\u00e7 birlikte kullan\u0131lm\u0131yor ve se\u00e7im \u00f6l\u00e7\u00fctleri farkl\u0131. G\u00fcncel monarchE sonu\u00e7lar\u0131 abemasiklib ile ya\u015fam s\u00fcresinde yarar g\u00f6sterirken, NATALEE\u2019nin uzun d\u00f6nem takibi ribosiklibin tekrarlama riskini azaltan etkisinin s\u00fcrd\u00fc\u011f\u00fcn\u00fc destekliyor. [2,3]\n<p>HER2 pozitif hastal\u0131kta tedavi, ameliyat \u00f6ncesi verilen ila\u00e7lara al\u0131nan yan\u0131ta g\u00f6re daha da ki\u015fiselle\u015fiyor. 2026\u2019da trastuzumab derukstekan adl\u0131 antikora ba\u011fl\u0131 kemoterapi, ABD\u2019de iki erken evre kullan\u0131m i\u00e7in onay ald\u0131: evre II\u2013III hastal\u0131kta ameliyat \u00f6ncesi belirli bir tedavi s\u0131ralamas\u0131n\u0131n par\u00e7as\u0131 olarak ve ameliyat \u00f6ncesi trastuzumab ile taksan i\u00e7eren tedaviye ra\u011fmen ameliyat \u00f6rne\u011finde canl\u0131 t\u00fcm\u00f6r kalan hastalarda ameliyat sonras\u0131 kullan\u0131m i\u00e7in. Bu se\u00e7enek de\u011ferlendirilirken akci\u011fer iltihab\u0131 dahil yan etkiler dikkatle izleniyor. [4]\n<p>\u00dc\u00e7l\u00fc negatif meme kanserinde, y\u00fcksek riskli erken evre hastalarda ameliyat \u00f6ncesi kemoterapiye pembrolizumab eklenmesi ve ameliyat sonras\u0131nda pembrolizumaba devam edilmesi ya\u015fam s\u00fcresini uzatabiliyor. Kal\u0131tsal BRCA1 veya BRCA2 de\u011fi\u015fikli\u011fi bulunan, HER2 negatif ve y\u00fcksek riskli hastalarda ise kemoterapi ve yerel tedaviler sonras\u0131nda olaparib ek bir se\u00e7enek olabiliyor. Bu nedenle uygun hastalarda genetik dan\u0131\u015fmanl\u0131k ve kal\u0131tsal gen testi tedavi karar\u0131na do\u011frudan katk\u0131 sa\u011fl\u0131yor. [5,6]\n<p>\u0130lerleme yaln\u0131zca yeni ila\u00e7lardan ibaret de\u011fil. Se\u00e7ilmi\u015f d\u00fc\u015f\u00fck riskli, lenf bezleri klinik de\u011ferlendirmede temiz olan hastalarda koltuk alt\u0131 lenf bezi \u00f6rneklemesinden vazge\u00e7ilebiliyor. Radyoterapide de uygun hastalarda bir haftal\u0131k, be\u015f seansl\u0131k uygulamalar tedavi y\u00fck\u00fcn\u00fc azalt\u0131yor; FAST-Forward\u2019\u0131n 2026 uzun d\u00f6nem sonu\u00e7lar\u0131 bu yakla\u015f\u0131m\u0131 destekliyor. Bu kararlar, gerekli tedaviyi eksiltmeden hastaya daha az y\u00fck getirmeyi ama\u00e7l\u0131yor. [7,8]\n<p>Her hastan\u0131n ihtiyac\u0131 ayn\u0131 de\u011fil. Yeni se\u00e7eneklerin beklenen yarar\u0131, olas\u0131 yan etkileri ve T\u00fcrkiye\u2019deki eri\u015fim ko\u015fullar\u0131 a\u00e7\u0131k\u00e7a konu\u015fulmal\u0131; tedavi boyunca hastan\u0131n sorular\u0131, kayg\u0131lar\u0131 ve g\u00fcnl\u00fck ya\u015fam\u0131 da plan\u0131n i\u00e7inde kalmal\u0131.<\/p>\n<p><strong>Kaynaklar \u00a0<\/strong><a href=\"https:\/\/www.cancer.gov\/news-events\/press-releases\/2018\/tailorx-breast-cancer-chemotherapy\">[1] TAILORx \u00b7 NCI<\/a>\u00a0\u00a0| \u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41110697\/\">[2] monarchE \u00b7 2026<\/a>\u00a0\u00a0| \u00a0<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12684762\/\">[3] NATALEE \u00b7 5 years<\/a>\u00a0\u00a0| \u00a0<a href=\"https:\/\/www.fda.gov\/drugs\/cancer-approvals\/fda-approves-two-separate-indications-fam-trastuzumab-deruxtecan-nxki-her2-positive-early-stage\">[4] HER2 \u00b7 FDA 2026<\/a>\u00a0\u00a0| \u00a0<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2409932\">[5] KEYNOTE-522 \u00b7 NEJM<\/a>\u00a0\u00a0| \u00a0<a href=\"https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2105215\">[6] OlympiA \u00b7 NEJM<\/a>\u00a0\u00a0| \u00a0<a href=\"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00099\">[7] ASCO \u00b7 2025<\/a>\u00a0\u00a0| \u00a0<a href=\"https:\/\/repository.icr.ac.uk\/items\/c6de6c48-22ab-4ee9-900e-fe0d8f2ca540\">[8] FAST-Forward \u00b7 2026<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Erken evre meme kanserinde tedavinin amac\u0131, hastal\u0131\u011f\u0131 ortadan kald\u0131rmak ve yeniden ortaya \u00e7\u0131kma riskini azaltmakt\u0131r. Son y\u0131llardaki geli\u015fmeler, bu hedefe ula\u015f\u0131rken kimin daha yo\u011fun tedaviye ihtiya\u00e7 duydu\u011funu, kimde ise baz\u0131 tedavilerin azalt\u0131labilece\u011fini daha iyi anlamam\u0131z\u0131 sa\u011fl\u0131yor. Kararlar; t\u00fcm\u00f6r\u00fcn \u00f6zellikleri, lenf bezlerinin durumu ve hastan\u0131n ya\u015fam\u0131 birlikte de\u011ferlendirilerek, cerrahi, t\u0131bbi onkoloji, radyasyon onkolojisi ve patoloji uzmanlar\u0131n\u0131n<\/p>","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3768","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Erken Evre Meme Kanseri Tedavisinde Yeni Geli\u015fmeler - \u00d6zel Tansan Poliklini\u011fi<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tansan.com.tr\/en\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Erken Evre Meme Kanseri Tedavisinde Yeni Geli\u015fmeler - \u00d6zel Tansan Poliklini\u011fi\" \/>\n<meta property=\"og:description\" content=\"Erken evre meme kanserinde tedavinin amac\u0131, hastal\u0131\u011f\u0131 ortadan kald\u0131rmak ve yeniden ortaya \u00e7\u0131kma riskini azaltmakt\u0131r. Son y\u0131llardaki geli\u015fmeler, bu hedefe ula\u015f\u0131rken kimin daha yo\u011fun tedaviye ihtiya\u00e7 duydu\u011funu, kimde ise baz\u0131 tedavilerin azalt\u0131labilece\u011fini daha iyi anlamam\u0131z\u0131 sa\u011fl\u0131yor. Kararlar; t\u00fcm\u00f6r\u00fcn \u00f6zellikleri, lenf bezlerinin durumu ve hastan\u0131n ya\u015fam\u0131 birlikte de\u011ferlendirilerek, cerrahi, t\u0131bbi onkoloji, radyasyon onkolojisi ve patoloji uzmanlar\u0131n\u0131n\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tansan.com.tr\/en\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00d6zel Tansan Poliklini\u011fi\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-17T20:32:23+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/\",\"url\":\"https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/\",\"name\":\"Erken Evre Meme Kanseri Tedavisinde Yeni Geli\u015fmeler - \u00d6zel Tansan Poliklini\u011fi\",\"isPartOf\":{\"@id\":\"https:\/\/tansan.com.tr\/#website\"},\"datePublished\":\"2026-11-17T18:43:38+00:00\",\"dateModified\":\"2026-11-17T20:32:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Ana sayfa\",\"item\":\"https:\/\/tansan.com.tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Erken Evre Meme Kanseri Tedavisinde Yeni Geli\u015fmeler\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tansan.com.tr\/#website\",\"url\":\"https:\/\/tansan.com.tr\/\",\"name\":\"Tansan Onkoloji - \u00d6zel Tansan Poliklini\u011fi\",\"description\":\"Kanser Te\u015fhis ve Tedavisi\",\"publisher\":{\"@id\":\"https:\/\/tansan.com.tr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tansan.com.tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/tansan.com.tr\/#organization\",\"name\":\"\u00d6zel Tansan Onkoloji Poliklini\u011fi\",\"url\":\"https:\/\/tansan.com.tr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png\",\"contentUrl\":\"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png\",\"width\":274,\"height\":66,\"caption\":\"\u00d6zel Tansan Onkoloji Poliklini\u011fi\"},\"image\":{\"@id\":\"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Erken Evre Meme Kanseri Tedavisinde Yeni Geli\u015fmeler - \u00d6zel Tansan Poliklini\u011fi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tansan.com.tr\/en\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/","og_locale":"en_GB","og_type":"article","og_title":"Erken Evre Meme Kanseri Tedavisinde Yeni Geli\u015fmeler - \u00d6zel Tansan Poliklini\u011fi","og_description":"Erken evre meme kanserinde tedavinin amac\u0131, hastal\u0131\u011f\u0131 ortadan kald\u0131rmak ve yeniden ortaya \u00e7\u0131kma riskini azaltmakt\u0131r. Son y\u0131llardaki geli\u015fmeler, bu hedefe ula\u015f\u0131rken kimin daha yo\u011fun tedaviye ihtiya\u00e7 duydu\u011funu, kimde ise baz\u0131 tedavilerin azalt\u0131labilece\u011fini daha iyi anlamam\u0131z\u0131 sa\u011fl\u0131yor. Kararlar; t\u00fcm\u00f6r\u00fcn \u00f6zellikleri, lenf bezlerinin durumu ve hastan\u0131n ya\u015fam\u0131 birlikte de\u011ferlendirilerek, cerrahi, t\u0131bbi onkoloji, radyasyon onkolojisi ve patoloji uzmanlar\u0131n\u0131n","og_url":"https:\/\/tansan.com.tr\/en\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/","og_site_name":"\u00d6zel Tansan Poliklini\u011fi","article_modified_time":"2026-11-17T20:32:23+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/","url":"https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/","name":"Erken Evre Meme Kanseri Tedavisinde Yeni Geli\u015fmeler - \u00d6zel Tansan Poliklini\u011fi","isPartOf":{"@id":"https:\/\/tansan.com.tr\/#website"},"datePublished":"2026-11-17T18:43:38+00:00","dateModified":"2026-11-17T20:32:23+00:00","breadcrumb":{"@id":"https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/tansan.com.tr\/erken-evre-meme-kanseri-tedavisinde-yeni-gelismeler\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Ana sayfa","item":"https:\/\/tansan.com.tr\/"},{"@type":"ListItem","position":2,"name":"Erken Evre Meme Kanseri Tedavisinde Yeni Geli\u015fmeler"}]},{"@type":"WebSite","@id":"https:\/\/tansan.com.tr\/#website","url":"https:\/\/tansan.com.tr\/","name":"Tansan Oncology - Tansan Private Polyclinic","description":"Cancer Diagnosis and Treatment","publisher":{"@id":"https:\/\/tansan.com.tr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tansan.com.tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/tansan.com.tr\/#organization","name":"Tansan Private Oncology Polyclinic","url":"https:\/\/tansan.com.tr\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/","url":"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png","contentUrl":"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png","width":274,"height":66,"caption":"\u00d6zel Tansan Onkoloji Poliklini\u011fi"},"image":{"@id":"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages\/3768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/comments?post=3768"}],"version-history":[{"count":2,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages\/3768\/revisions"}],"predecessor-version":[{"id":3799,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages\/3768\/revisions\/3799"}],"wp:attachment":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/media?parent=3768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}